Admera Health Adds Clinical Genomics Expert, Dr. Ruben Bonilla-Guerrero, to Management Team
South Plainfield, NJ – December 04 2018 – Admera Health, a molecular diagnostic company, welcomes Dr. Ruben Bonilla-Guerrero as Medical Director to the company. Ruben Bonilla-Guerrero obtained his M.D. from the Universidad Veracruzana in Mexico followed by 14 years working experience at Mayo Clinic in Minnesota, including fellowships in [...]
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
South Plainfield, NJ – October 23, 2018 - At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based LiquidGx™ test for solid tumor-targeted therapy selection from a blood sample. This extended version increases the utility of the assay by raising the [...]
Admera Health Teams with Allure Specialty Pharmacy to Offer PharmD Fellowship Program
South Plainfield, NJ – September 25, 2018 - Today, Admera Health, a molecular diagnostics company, in conjunction with Allure Specialty Pharmacy announced the launch of a Post-Doctoral PharmD Fellowship Program focused on pharmacogenomics. The Admera Health-Allure Specialty Pharmacy Program is a multi-site fellowship program that includes two longitudinal experiences [...]
Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health
SYRACUSE, N.Y., Aug. 8, 2018 /PRNewswire/ — Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ. The partnership brings together two companies that have been identified as innovators within [...]
Admera Health Announces Availability of Psychiatric Specific Report, PGxPsych™, for its PGxOne™ Plus Pharmacogenomics Test
South Plainfield, NJ – June 26, 2018 - Today, Admera Health (www.admerahealth.com), announced the availability of a psychiatric specific report for its PGxOne™ Plus pharmacogenomics test. PGxOne™ Plus is a laboratory developed test that includes over 50 genes, over 200 DNA variants (affecting drug metabolism, transportation, and activation), and provides [...]